Codeine
Codeine is a milder opioid used for pain and cough; it converts to morphine in the body, carries opioid overdose and dependence risk, and is dangerous mixed with other depressants.
Overview
Codeine is an opioid used to treat mild-to-moderate pain and, in some products, to suppress cough. It is generally milder than morphine, but it belongs to the same drug class and carries the same fundamental opioid risks — dependence, and dangerous-to-fatal respiratory depression in overdose or in combination with other depressants. Codeine is found in prescription tablets and in combination cough and pain products; some preparations have historically been available with fewer restrictions in certain places, which has contributed to misuse (for example in sweetened drink mixtures). Because the body converts codeine into morphine, how strongly it affects a given person depends partly on individual metabolism, which makes its effects less predictable than they might seem.
Source: MedlinePlus; DEA; PubChem CID 5284371
Chemistry & mechanism of action
Codeine is itself relatively weak at opioid receptors; most of its effect comes from being converted in the body (by the liver enzyme CYP2D6) into morphine, which then activates mu-opioid receptors to relieve pain and produce sedation and euphoria. Because people vary widely in how fast they make this conversion, the same dose can produce very different effects: "ultra-rapid metabolizers" can generate unexpectedly high morphine levels and are at greater risk of dangerous breathing suppression, which is why codeine is considered especially hazardous in children and in some individuals. Like all opioids, codeine suppresses the brain-stem control of breathing, and repeated use produces tolerance and physical dependence.
Source: MedlinePlus; PubChem CID 5284371
Effects
At usual doses codeine relieves pain and suppresses cough, and commonly causes drowsiness, constipation, nausea, dry mouth, and a mild sense of calm or euphoria. Higher doses bring stronger sedation, confusion, and the opioid-class danger of slowed, shallow breathing. With repeated use, tolerance and physical dependence develop, and stopping after regular use brings opioid withdrawal — restlessness, aches, insomnia, sweating, nausea, and craving. Because effects depend on individual metabolism, some people experience stronger-than-expected effects from a standard dose.
Source: MedlinePlus
Risks & harms
Although codeine is milder than morphine, it is still an opioid, and the central danger remains respiratory depression — slowed or stopped breathing — which becomes much more likely at high doses, in fast metabolizers, and when codeine is combined with other depressants. Mixing codeine with alcohol, benzodiazepines, or other opioids compounds the suppression of breathing and can be fatal; a particular hazard is combining codeine cough syrup with alcohol or sedatives. Codeine is especially dangerous for children and for people who metabolize it rapidly. Naloxone (Narcan) reverses an opioid overdose, is available over the counter in the U.S. since 2023, and is safe to give even if opioids turn out not to be involved — give it if available and call 911 for slow or stopped breathing or unresponsiveness. Anything sold as codeine outside a pharmacy carries the broader illicit-supply risk of contamination with stronger opioids such as fentanyl. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: MedlinePlus; DEA; SAMHSA
Legal status (US)
In the United States, codeine's legal status depends on the product: codeine on its own and higher-strength formulations are Schedule II controlled substances, while certain low-dose combination products (for example some cough preparations) fall into less restrictive schedules. In all cases it is a prescription drug, and possessing or selling it without a valid prescription is illegal. Internationally, codeine is controlled under the United Nations Single Convention on Narcotic Drugs, though the exact restrictions — including whether low-dose products are available without prescription — vary by country. For country-by-country legal detail, see our legality pages.
Source: DEA; UN Single Convention on Narcotic Drugs (1961)
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With opioids, slowed or stopped breathing is the emergency, if available, give naloxone and call 911 immediately; it can be given while you wait for help.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 5284371PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-olPubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C18H21NO3PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)OPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- OROGSEYTTFOCAN-DNJOTXNNSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- Methylmorphine, Codicept, Codeine anhydrous, Coducept, l-Codeine, Morphine monomethyl ether, (-)-Codeine, O3-Methylmorphine, codeinum, CODEINE BASEPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- 3 DOSAGE FORMS AND STRENGTHS Each 15 mg tablet for oral administration contains 15 mg of codeine sulfate, USP. It is a white to off-white biconvex tablet with “openFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Codeine is a comparatively mild natural opioid used for pain and, in some products, to suppress cough. It is a prodrug: the body converts part of it to morphine, which produces most of its effect, so how strongly it works depends heavily on an individual's metabolism. Taken as intended it gives modest opioid pain relief along with drowsiness and relaxation. That reliance on metabolic conversion is what makes its effect — and its risk — vary so much from person to person.NIDA Opioids + PubChem CID 5284371 ↗ · retrieved 2026-06-18
- Risks
- How strongly codeine acts differs between people because of variation in the liver enzyme (CYP2D6) that turns it into morphine. "Ultra-rapid metabolisers" can generate unexpectedly high morphine levels and suffer dangerous respiratory depression from an ordinary amount — a risk that led to strong warnings against giving codeine to children and to people who are breastfeeding. Beyond that, codeine carries the opioid class's core hazard: overdose kills through respiratory depression, and the danger rises when it is combined with alcohol or other depressants. Constipation, nausea, tolerance and dependence occur. Treated in time, an opioid overdose responds to naloxone.NIDA Opioids + PubChem CID 5284371 ↗ · retrieved 2026-06-18
- Interactions
- Codeine's approved labelling gives particular weight to drugs affecting the CYP2D6 and CYP3A4 enzymes that govern its conversion to morphine: inhibitors and inducers can unpredictably raise or lower the active opioid level and, with it, the danger. As with the class, pairing codeine with benzodiazepines, alcohol or other sedatives can lead to dangerous over-sedation and life-threatening suppression of breathing. The label also cautions against serotonergic drugs, which can contribute to serotonin syndrome, and against monoamine-oxidase inhibitors.DailyMed Codeine Sulfate §7 Drug Interactions ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 93different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 93 variants
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NuCare Pharmaceuticals,Inc.
- Schedule
- CIII
- NDC
- 68071-5010 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 15 mg/1
- Imprint
- 2 M
- Color
- white
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SpecGx LLC
- Schedule
- CIII
- NDC
- 0406-0483 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 15 mg/1
- Imprint
- W241
- Color
- PINK
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Eywa Pharma Inc
- Schedule
- CII
- NDC
- 71930-054 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- W242
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Eywa Pharma Inc
- Schedule
- CIII
- NDC
- 71930-055 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 60 mg/1
- Imprint
- W243
- Color
- BLUE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Eywa Pharma Inc
- Schedule
- CIII
- NDC
- 71930-056 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; BUTALBITAL 50 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE
- Imprint
- FIORICET CODEINE
- Color
- blue
- Shape
- CAPSULE
- Form
- CAPSULE
- Labeler
- Actavis Pharma, Inc.
- Schedule
- CIII
- NDC
- 52544-082 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- CAPSULE
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIII
- NDC
- 71335-0194 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 60 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIII
- NDC
- 63629-1190 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ST. MARY'S MEDICAL PARK PHARMACY
- Schedule
- CIII
- NDC
- 60760-938 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 60 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIII
- NDC
- 67544-003 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NuCare Pharmaceuticals, Inc.
- Schedule
- CIII
- NDC
- 68071-3798 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 60 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NuCare Pharmaceuticals,Inc.
- Schedule
- CIII
- NDC
- 68071-2681 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIII
- NDC
- 67544-002 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 60 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIII
- NDC
- 71335-2818 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Redpharm Drug
- Schedule
- CIII
- NDC
- 67296-2239 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIII
- NDC
- 71335-0256 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 60 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Clinical Solutions Wholesale, LLC
- Schedule
- CIII
- NDC
- 58118-0485 ↗ · 2026-06-18
- Strength
- CODEINE SULFATE 60 mg/1
- Imprint
- 60 54 412
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Hikma Pharmaceuticals USA Inc.
- Schedule
- CII
- NDC
- 0054-0245 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; BUTALBITAL 50 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE
- Imprint
- 54 640
- Color
- BLUE
- Shape
- CAPSULE
- Form
- CAPSULE
- Labeler
- Hikma Pharmaceuticals USA Inc.
- Schedule
- CIII
- NDC
- 0054-0650 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NuCare Pharmaceuticals, Inc.
- Schedule
- CIII
- NDC
- 68071-3824 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- 3 M
- Color
- white
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SpecGx LLC
- Schedule
- CIII
- NDC
- 0406-0484 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Unit Dose Solutions, Inc.
- Schedule
- CIII
- NDC
- 87441-009 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Proficient Rx LP
- Schedule
- CIII
- NDC
- 63187-815 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; CODEINE PHOSPHATE 60 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Direct_Rx
- Schedule
- CIII
- NDC
- 72189-376 ↗ · 2026-06-18
Dosage
Pending medical reviewer
